|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
rs121913529
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We hypothesized that tumor progression was because of concomitant activation of the mitogen-activated protein kinase pathway downstream of Kras(G12D) expression promoting cell survival and that the therapeutic effect of PF-04691502 would be enhanced by combinatory inhibition of MEK using PD-0325901.
|
21632463 |
2011 |
|
rs121913529
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression.
|
21859834 |
2011 |
|
rs1284806277
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Besides earlier described DNA methylation, recent studies implicate bone morphogenic protein and non-steroidal anti-inflammatory drugs in control of S100P expression during tumor progression.
|
20155429 |
2011 |
|
rs752021744
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We hypothesized that tumor progression was because of concomitant activation of the mitogen-activated protein kinase pathway downstream of Kras(G12D) expression promoting cell survival and that the therapeutic effect of PF-04691502 would be enhanced by combinatory inhibition of MEK using PD-0325901.
|
21632463 |
2011 |
|
rs104894230
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression.
|
21859834 |
2011 |
|
rs1285136498
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Besides earlier described DNA methylation, recent studies implicate bone morphogenic protein and non-steroidal anti-inflammatory drugs in control of S100P expression during tumor progression.
|
20155429 |
2011 |
|
rs1418810723
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
rs438034
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, the 52 single nucleotide polymorphisms associated at P<10(-4) included rs438034 (CENPF; P=4.86×10(-6)), previously correlated with cancer progression, and rs2255235 (B2M; P=3.10×10(-5)) and rs2064501 (IL22RA2; P=4.81×10(-5)) which map to B-cell genes.
|
21659360 |
2011 |
|
rs4986790
|
|
|
0.010 |
GeneticVariation |
BEFREE |
TLR4-D299G induces features of neoplastic progression in intestinal epithelial Caco-2 cells and associates with aggressive colon cancer in humans, implying a novel link between aberrant innate immunity and colonic cancerogenesis.
|
21920464 |
2011 |
|
rs4986791
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Caco-2 cells that expressed TLR4-D299G underwent the epithelial-mesenchymal transition and morphologic changes associated with tumor progression, whereas cells that expressed wild-type TLR4 or TLR4-T399I did not.
|
21920464 |
2011 |
|
rs727503094
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression.
|
21859834 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Oncogenic B-RAF V600E mutation is found in 50% of melanomas and drives MEK/ERK pathway and cancer progression.
|
22730329 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Correspondingly, in established murine BRAF(V600E)-driven nevi, acute shRNA-mediated depletion of PTEN prompted tumor progression.
|
22549727 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Oncogenic B-RAF V600E mutation is found in 50% of melanomas and drives MEK/ERK pathway and cancer progression.
|
22730329 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Correspondingly, in established murine BRAF(V600E)-driven nevi, acute shRNA-mediated depletion of PTEN prompted tumor progression.
|
22549727 |
2012 |
|
rs121913529
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Other organs such as pancreas, liver, and small intestine do not exhibit neoplastic progression within 6 weeks following K-Ras(G12D) activation and do not show a potent tumor suppressor response.
|
22532587 |
2012 |
|
rs752021744
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Additionally, we tested efficacy of PD-0325901 in Kras(G12D-LSL) conditional GEMMs (genetically engineered mouse models) which are a valuable tool in translational research to study tumor progression.
|
22684718 |
2012 |
|
rs762846821
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The concomitant expression of oncogenic Kras(G12D) and mutant p53 (Trp53(R172H)) in the murine pancreas results in metastatic PDA that recapitulates the cognate features of human pancreatic cancer providing an excellent animal model to identify genes required for tumor progression.
|
22158044 |
2012 |
|
rs10009228
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A SNP in the alpha9 subunit, the G allele of rs10009228 (alpha9, A>G) shows a significant trend in the combined cohort, indicating that this allele constitutes a risk factor for neoplastic progression.
|
22406075 |
2012 |
|
rs1057519847
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression.
|
23143308 |
2012 |
|
rs1057519848
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression.
|
23143308 |
2012 |
|
rs121434568
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression.
|
23143308 |
2012 |
|
rs1695
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The current data, based on a large cohort (n = 929) of Chinese patients with gastric cancer, suggested that the presence of SOD2 rs4880 and GSTP1 rs1695 genotypes may contribute to cancer progression as well as tumor aggressiveness.
|
22517484 |
2012 |